ATE57470T1 - Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung. - Google Patents

Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung.

Info

Publication number
ATE57470T1
ATE57470T1 AT85109688T AT85109688T ATE57470T1 AT E57470 T1 ATE57470 T1 AT E57470T1 AT 85109688 T AT85109688 T AT 85109688T AT 85109688 T AT85109688 T AT 85109688T AT E57470 T1 ATE57470 T1 AT E57470T1
Authority
AT
Austria
Prior art keywords
liquid
mixture
solid
polyethylene glycols
degrees
Prior art date
Application number
AT85109688T
Other languages
German (de)
English (en)
Inventor
Hans Dr Dipl-Chem Koehne
Wolfgang Lahr
Uwe Hein Dr Schmersahl
Original Assignee
Rentschler Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6248592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE57470(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rentschler Arzneimittel filed Critical Rentschler Arzneimittel
Application granted granted Critical
Publication of ATE57470T1 publication Critical patent/ATE57470T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
AT85109688T 1984-10-23 1985-08-01 Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung. ATE57470T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19843438830 DE3438830A1 (de) 1984-10-23 1984-10-23 Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
EP85109688A EP0182007B1 (de) 1984-10-23 1985-08-01 Nifedipin enthaltende Darreichungsform und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ATE57470T1 true ATE57470T1 (de) 1990-11-15

Family

ID=6248592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85109688T ATE57470T1 (de) 1984-10-23 1985-08-01 Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung.

Country Status (5)

Country Link
US (1) US4894235A (enExample)
EP (1) EP0182007B1 (enExample)
JP (1) JPS61100528A (enExample)
AT (1) ATE57470T1 (enExample)
DE (2) DE3438830A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
DE3635522A1 (de) * 1986-10-18 1988-04-28 Euro Celtique Sa Pharmazeutische zusammensetzung
ATE68704T1 (de) * 1986-12-18 1991-11-15 Bauer Kurt Heinz Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
KR920700613A (ko) * 1989-05-16 1992-08-10 지구르트 퓌터 약제제
CA2056032A1 (en) * 1990-11-29 1992-05-30 Minoru Aoki Hard capsule preparation
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
JP3148256B2 (ja) 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6537504B1 (en) 1998-04-06 2003-03-25 Li Young Method and apparatus for concurrent and sequential multi-step reactions for producing a plurality of different chemical compounds
HK1042427A1 (zh) * 1999-09-30 2002-08-16 Penwest Pharmaceuticals Co. 用於高溶度药物的持续释放基质方法
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
CA2450762A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
CN1681479A (zh) 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
EP1844078B1 (en) 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
KR100614032B1 (ko) * 2005-02-21 2006-08-22 주식회사 서흥캅셀 피막 강도를 개선시킨 젤라틴 경질캅셀
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
PL2280704T3 (pl) * 2008-03-31 2015-10-30 Cymabay Therapeutics Inc Związki oksymetylenoarylowe i ich zastosowania
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CU24395B1 (es) 2014-03-17 2019-04-04 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN105092659B (zh) * 2015-08-28 2017-11-03 云南大学 基于Pt掺杂SnO2有序介孔薄膜的气体传感器制备方法
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
SG10202110112TA (en) 2017-03-10 2021-10-28 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ
AU2020260018A1 (en) 2019-04-19 2021-11-04 Pfizer Inc. Anti-proliferative agents for treating PAH
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
IL312296A (en) 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
US12637461B2 (en) 2022-10-18 2026-05-26 Pfizer Inc. Compounds for the activation of AMPK
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
EP4604955A1 (en) 2022-10-18 2025-08-27 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3297804A (en) * 1964-05-19 1967-01-10 Ono Pharmaceutical Co Method of filling hard capsules with granules by the open-mouth-down punching method
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
SU432703A3 (enExample) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
DE2209526C3 (de) * 1972-02-29 1980-02-28 Bayer Ag, 5090 Leverkusen Coronartherapeutlkum in Form von Gelatine-BeiBkapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
DE2614864C3 (de) * 1976-04-06 1979-11-29 Schwabe, Willmar, Dr., 7500 Karlsruhe Verfahren zur Herstellung Digoxin enthaltender Arzneipräparate in Weichgelatinekapseln zur oralen Verabfolgung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
JPS5522631A (en) * 1978-08-07 1980-02-18 Ota Seiyaku Kk Readily absorbable nifedipine preparation
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4454152A (en) * 1980-05-07 1984-06-12 Hoffmann-La Roche Inc. Methoxsalen dosage forms
DE3022137A1 (de) * 1980-06-13 1982-01-07 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zum abfuellen von bei raumtemperatur hochviskosen pharmazeutischen massen in hartkapseln
US4310543A (en) * 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
JPS5785316A (en) * 1980-11-14 1982-05-28 Kanebo Ltd Preparation of easily absorbable nifedipine preparation
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
JPS58109412A (ja) * 1981-12-23 1983-06-29 Toa Eiyou Kagaku Kogyo Kk ニフエジピン固形製剤
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
JPS61100528A (ja) 1986-05-19
JPH0579651B2 (enExample) 1993-11-04
EP0182007A3 (en) 1987-04-22
DE3580154D1 (de) 1990-11-22
EP0182007A2 (de) 1986-05-28
US4894235A (en) 1990-01-16
DE3438830A1 (de) 1986-04-30
EP0182007B1 (de) 1990-10-17
DE3438830C2 (enExample) 1991-04-11

Similar Documents

Publication Publication Date Title
DE3580154D1 (de) Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung.
IT1138450B (it) Derivati dell'acido 2-idrossi-5-fenilazobenzoico,composizioni farmaceutiche che li contengono e procedimento per la loro preparazione
PT67365A (fr) Procede pour la preparation d'une composition pharmaceutique contenant des nouveaux composes organiques
FR2489982B1 (fr) Composition pour l'amorcage de la photopolymerisation contenant des composes n-oxy-n-heterocycliques comme activateurs
BE853733A (fr) Nouveaux nitroaminophenols substitues, leur procede d'obtention et compositions tinctoriales les contenant
FR2566773B1 (fr) Nouveaux benzamides substitues, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
PT66174B (fr) Procede pour la preparation de derives de ditiole-1,2 et de compositions qu'en contiennent
IT8019992A0 (it) Derivati dell'acido 3-fosfonocefalosporanico, procedimenti per la loro preparazione e composizione farmaceutica che li comprende.
PT66120A (fr) Procede pour la preparation d'une composition pharmaceutique contenant des nouveaux composes organiques
PT66186A (fr) Procede pour la preparation d'une composition pharmaceutique avec nouveaux composes organiques
KR950007840A (ko) 완하제 조성물
IT8024152A0 (it) Derivati dell'1,1,2-trifenilpropano e dell'1,1,2-trifenilpropene, procedimento per la loro preparazione e composizioni farmaceutiche contenenti i composti
JPS56112975A (en) Rust-preventing material for automobile and rust- preventing treatment
PT67623B (pt) Procede pour la preparation d'une composition pharmaceutique contenant des nouveaux composes organiques
IT1092701B (it) Etere cis-e trans-3,3,5-trimetilcicloesiletilic o e loro miscugli come profumi,composizioni di profumi che li contengono e processo di produzione migliorato dell'etere trans-3,3,5-trimetil-cicloesil-etilico
DE59107545D1 (de) Salicylaldehyd- und Salicylsäurederivate sowie deren Schwefelanaloge, Verfahren und Zwischenprodukte zu ihrer Herstellung
BE812562A (fr) Nouveaux derives substitues d'halogenotriazines utiles comme activateurs dans les compositions de blanchiment peroxygenees et compositions les contenant
PT68216A (fr) Procede pour la preparation d'une composition pharmaceu- tique contenant des nouveaux composes organiques
FR2703908B1 (fr) Forme pharmaceutique pour administration rectale de composés pharmacologiquement actifs.
ES485157A1 (es) Procedimiento para la obtencion de esteres de acido benzimi-dazolilcarbamico,de efecto antihelmintico
PT76428B (de) Verfahren zur herstellung von neuen derivaten des indolizino <8,7-b>-indols
PT66166B (fr) Procede pour la preparation d'une composition pharmaceutique contenant nouveaux composes organiques
PT66551B (fr) Procede pour la preparation d'une composition pharmaceutique avec des nouveaux composes organiques
JPS51135996A (en) Continuous process for pr oducing low molecular weight polypropylene
PT68218A (fr) Procede pour la preparation d'une composition pharmaceu- tique contenant des nouveaux composes organiques

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee